• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Henry Schein Inc.

    5/24/24 4:06:05 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    8-K
    HENRY SCHEIN INC false 0001000228 0001000228 2024-05-21 2024-05-21

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2024

     

     

    Henry Schein, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   0-27078   11-3136595
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    135 Duryea Road, Melville, New York   11747
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (631) 843-5500

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $.01 per share   HSIC   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 21, 2024, at the Henry Schein, Inc. (the “Company”) 2024 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved the amendment and restatement of the Henry Schein, Inc. 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan”), renamed the Henry Schein, Inc. 2024 Stock Incentive Plan (the “2024 Stock Incentive Plan”). The amendment and restatement incorporates the following changes:

     

      •  

    Increase of the Aggregate Share Reserve. The aggregate share reserve was increased by an additional 4,800,000 shares of common stock for a maximum total share reserve of 75,742,657 shares of common stock under the 2024 Stock Incentive Plan, subject to antidilution adjustments set forth in the 2024 Stock Incentive Plan.

     

      •  

    Increase of Individual Participant Limitations. The 2024 Stock Incentive Plan’s individual participant annual limitation on shares of common stock subject to any type of award under the 2024 Stock Incentive Plan was increased to a maximum of 750,000 shares of common stock, subject to antidilution adjustments set forth in the 2024 Stock Incentive Plan.

     

      •  

    Extend the Term. The term of the 2024 Stock Incentive Plan was extended until March 31, 2034 (the 2020 Stock Incentive Plan was scheduled to expire on March 31, 2030).

     

      •  

    Clawbacks: The 2024 Stock Incentive Plan was amended to clarify that any awards granted pursuant to the 2024 Stock Incentive Plan are subject to the terms and conditions of (i) the Company’s Incentive Compensation Recoupment Policy, effective as of February 1, 2016, (ii) the Company’s Dodd-Frank Clawback Policy, effective as of December 1, 2023 and (iii) any other clawback and/or recoupment policy approved by the Board of Directors of the Company from time to time, in each case, as amended from time to time and to the extent set forth in each applicable policy.

    In addition, the Board of Directors of the Company also adopted certain other minor clarifying amendments to the 2024 Stock Incentive Plan, which do not require stockholder approval, to reflect developments in applicable law and equity compensation practices.

    The foregoing summary of the 2024 Stock Incentive Plan does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2024 Stock Incentive Plan, which is attached as Exhibit 10.1 and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting, the Company’s stockholders considered: (1) a proposal to consider approval of the election of thirteen directors of the Company for terms expiring in 2025; (2) a proposal to consider amending and restating the 2020 Stock Incentive Plan (to be renamed the 2024 Stock Incentive Plan); (3) a proposal to consider approval, by non-binding vote, of the 2023 compensation paid to the Company’s Named Executive Officers (as defined in the proxy statement) (commonly known as a “say-on-pay” proposal); and (4) a proposal to consider the ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 28, 2024. The voting results at the Annual Meeting, with respect to each of the matters described above, are set forth below.


      1.

    The thirteen directors of the Company were elected to serve for terms expiring in 2025 based upon the following votes:

     

         For      Against      Abstain      Broker
    Non-Votes
     

    Mohamad Ali

         113,889,137        1,530,281        87,272        5,595,916  

    Stanley M. Bergman

         105,036,640        10,076,387        393,663        5,595,916  

    Deborah Derby

         111,379,251        4,055,144        72,295        5,595,916  

    Carole T. Faig

         113,896,008        1,539,068        71,614        5,595,916  

    Joseph L. Herring

         114,412,564        1,009,834        84,292        5,595,916  

    Kurt P. Kuehn

         113,714,791        1,707,570        84,329        5,595,916  

    Philip A. Laskawy

         101,874,674        13,235,174        396,842        5,595,916  

    Anne H. Margulies

         114,746,966        688,131        71,593        5,595,916  

    Mark E. Mlotek

         113,865,228        1,561,667        79,795        5,595,916  

    Carol Raphael

         114,512,998        921,528        72,164        5,595,916  

    Scott Serota

         114,861,772        571,388        73,530        5,595,916  

    Bradley T. Sheares, Ph.D.

         109,221,411        6,217,216        68,063        5,595,916  

    Reed V. Tuckson, M.D., FACP

         114,800,620        623,788        82,282        5,595,916  

     

      2.

    The amendment and restatement of the 2020 Stock Incentive Plan (to be renamed the 2024 Stock Incentive Plan) was approved based upon the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    103,389,108   12,007,164   110,418   5,595,916

     

      3.

    The 2023 compensation paid to the Company’s Named Executive Officers, commonly known as the “say-on-pay” proposal, was approved, by non-binding vote, based upon the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    101,447,636   13,912,806   146,248   5,595,916

     

      4.

    The appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 28, 2024 was ratified based upon the following votes:

     

    For

     

    Against

     

    Abstain

    114,746,691   6,236,274   119,641

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    10.1    Henry Schein, Inc. 2024 Stock Incentive Plan, as amended and restated effective as of May 21, 2024
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       

    HENRY SCHEIN, INC.

    (Registrant)

    Date: May 24, 2024     By:  

    /s/ Kelly Murphy

          Kelly Murphy
          Senior Vice President and General Counsel
    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Global Dist. & Tech. Albertini Andrea covered exercise/tax liability with 2,032 shares, decreasing direct ownership by 3% to 65,900 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/11/25 4:14:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/9/25 9:05:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 140 units of Common Stock par value $0.01 per shre and gifted 500 shares, decreasing direct ownership by 0.20% to 319,877 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    11/26/25 4:10:29 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 4:05:30 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 7:00:20 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Third Quarter 2025 Conference Call on Tuesday, November 4, 2025, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2025 financial results before the stock market opens on Tuesday, November 4, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Sc

    10/21/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care